Emerald Health Therapeutics
5820 Nancy Ridge Dr
8 articles with Emerald Health Therapeutics
Emerald Health Therapeutics Enters Research Agreement with VivaCell Biotechnologies to Evaluate Proprietary Cannabis Products
Emerald Health Therapeutics, Inc. has entered into a research agreement with VivaCell Biotechnologies Spain S.L.U.
CFN Media Group announces publication of an article covering Emerald Health Therapeutics Inc.'s (TSX-V: EMH) (OTCQX: EMHTF) recent acquisition of a dealer license from Abattis Bioceuticals Corp. that enables it to compete in emerging market verticals.
Emerald Health Therapeutics, Inc. is providing an update on its differentiated strategy to excel in the growing cannabis industry.
Emerald Health Therapeutics Welcomes Historic Passing of Bill C-45 to Legalize Adult-Use Cannabis in Canada
Emerald Health Therapeutics, Inc. applauds the Canadian government’s historic passing of Bill C-45 (Cannabis Act) to end Canada’s near century-long prohibition of recreational cannabis and usher in a new era of cannabis regulation.
Each Unit consisted of one common share of the Company and one common share purchase warrant (a “Warrant”).
Senior marketing executive with three decades global consumer packaged goods experience to lead Emerald’s marketing and sales strategy.
The Options have been granted pursuant to the Company’s Omnibus Incentive Plan which has been previously approved by the Company’s shareholders and the TSX Venture Exchange.
The Company announces that it is not aware of any material, undisclosed corporate developments and has no material change to report at this time.